🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hutchmed clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Hutchmed as lead sponsor. Synced 26 Sep 2026
14Current trials
9Recruiting now
12Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hutchmed is the lead sponsor of 14 current clinical trials in our China and USA registers. 9 are recruiting patients now. The most common phase is Phase 2/3. The drugs named most often in its trials are Fruquintinib, HMPL-306 and Sintilimab. The most-studied condition is Solid Tumors, Adult.

ClinicalTrials.gov trials by status

  • Recruiting964%
  • Not yet open17%
  • Active, closed429%

Trials by phase

  • Phase 2/3429%
  • Phase 3429%
  • Phase 1/2321%
  • Phase 1214%
  • Phase 217%
01

Clinical trials sponsored by Hutchmed

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
NCT04353375 · ClinicalTrials.gov ↗ · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
Phase 2/3 Recruiting 2020-09 China
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247 · ClinicalTrials.gov ↗ · Solid Tumors, Adult
Phase 1/2 Recruiting 2025-12 USA, China
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032 · ClinicalTrials.gov ↗ · Advanced Endometrial Cancer
Phase 3 Recruiting 2024-12 China
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
NCT07025018 · ClinicalTrials.gov ↗ · Gliomas Harboring IDH1 and/or IDH2 Mutations
Drug: HMPL-306
Phase 1 Recruiting 2025-07 China
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082 · ClinicalTrials.gov ↗ · Hematological Malignancies
Phase 1 Recruiting 2024-05 China
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
NCT07396584 · ClinicalTrials.gov ↗ · Solid Tumors, Adult
Phase 1/2 Recruiting 2026-03 USA, China
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Drug: HMPL-306
Phase 3 Recruiting 2024-04 China
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3 Recruiting 2026-03 China
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer
Phase 2/3 Recruiting 2024-05 China
HMPL-A830 in Solid Tumors
NCT07718581 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
Phase 1/2 Not yet open 2026-08 China
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma
Phase 2/3 Active, closed 2022-10 China
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2 Active, closed 2024-11 China
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT05009836 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 3 Active, closed 2021-09 China
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933 · ClinicalTrials.gov ↗ · Warm Antibody Autoimmune Hemolytic Anemia
Phase 2/3 Active, closed 2022-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hutchmed trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hutchmed trials

12 conditions
Solid Tumors, Adult2Solid Tumor, Adult2Relapsed/Refractory Diffuse Large B-Cell Lymphoma2Advanced Intrahepatic Cholangiocarcinoma1Advanced Endometrial Cancer1Gliomas Harboring IDH1 and/or IDH2 Mutations1Advanced Renal Cell Carcinoma1Hematological Malignancies1Acute Myeloid Leukemia1Non-small Cell Lung Cancer1Warm Antibody Autoimmune Hemolytic Anemia1Metastatic Pancreatic Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China149
Clinical trials in USA22

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Solid Tumors, Adult

SponsorTrials
Grit Biotechnology2
HighField Biopharmaceuticals Corporation1
Wuxi People's Hospital1

Sponsors with the most current trials registered for this condition.

06

Questions about Hutchmed trials

How many clinical trials does Hutchmed sponsor?

Hutchmed is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hutchmed trials recruiting?

Yes. 9 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hutchmed testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Fruquintinib (2), HMPL-306 (2), Sintilimab (2), Doxorubicin (1) and Gemcitabine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.